Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium in Treating Subarachnoid Hemorrhage Related Vasospasm
NCT04613960Phase 3Unknown
- Sponsor
- General Authority for Teaching Hospitals and Institutes
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) and cerebral vasospasm comparing Magnesium arm with Placebo arm (2 arms). Primary endpoint: Clinical evidence and TCD measured MFV indicative of vasospasm at 14 days. Status: unknown.
02
Drugs
magnesium sulfate
03
Conditions
subarachnoid hemorrhage (SAH)cerebral vasospasm
Beyond the preview
Go deeper on NCT04613960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613960.